FIGURE LEGENDS
Figure 1. Side by side comparison of coronal CT imaging on
diagnosis notable for significant ascites and large mass (A) ,
relapse with recurrent ascites (B) , and after 5 years on
crizotinib therapy without malignant ascites and persistent necrotic
mass (C).
Figure 2. Immunohistochemistry (IHC) for ALK demonstrated high
expression throughout tumor samples. No pathologic mutations or gene
rearrangements in ALK were identified on sequencing, but gross oncogenic
over-expression of ALK was noted by IHC indicating ALK as a potential
therapeutic target.